Lormetazepam

Lormetazepam
Clinical data


Trade names	Noctamid, Loramet
AHFS/Drugs.com	International Drug Names
Pregnancy category	D
Routes of administration	Oral W
ATC code	N05CD06 (WHO)
Legal status
Legal status	CA: Schedule IV DE: Anlage III (Prescription only) US: Schedule IV
Pharmacokinetic data
Bioavailability	80%
Metabolism	Hepatic
Biological half-life	10–12 hours
Excretion	Renal
Identifiers
IUPAC name 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one
Synonyms	methyl-lorazepam, N-methyllorazepam
CAS Number	848-75-9^N
PubChem CID	13314
IUPHAR/BPS	7553
ChemSpider	12750^Y
UNII	GU56C842ZA
KEGG	D01657^Y
ChEBI	CHEBI:52993^Y
ChEMBL	CHEMBL22097^Y
ECHA InfoCard	100.011.546
Chemical and physical data
Formula	C₁₆H₁₂Cl₂N₂O₂
Molar mass	335.2 g/mol
3D model (Jmol)	Interactive image
SMILES ClC1=CC=CC=C1C2=NC(C(N(C)C3=C2C=C(C=C3)Cl)=O)O
InChI InChI=1S/C16H12Cl2N2O2/c1-20-13-7-6-9(17)8-11(13)14(19-15(21)16(20)22)10-4-2-3-5-12(10)18/h2-8,15,21H,1H3^Y Key:FJIKWRGCXUCUIG-UHFFFAOYSA-N^Y
^NY (what is this?)

Oral

Lormetazepam (INN, or methyl-lorazepam, is a drug which is a short to intermediate acting 3-hydroxybenzodiazepine derivative. It possesses hypnotic, anxiolytic, anticonvulsant, sedative, and skeletal muscle relaxant properties.

Lormetazepam is not approved for sale in the United States or Canada. It is licensed in the UK as 0.5 and 1 mg tablets for short-term treatment (2–4 weeks) of moderately severe insomnia. It is licensed in the Netherlands as 1 and 2 mg tablets, under the brand names Loramet and Noctamid and as generic, available from several manufacturers. It is sold in Poland as Noctofer.

The Dutch, British, and French system called the System of Objectified Judgement Analysis for assessing whether drugs should be included in drug formularies based on clinical efficacy, adverse effects, pharmacokinetic properties, toxicity, and drug interactions was used to assess lormetazepam. A Dutch analysis using the system found that lormetazepam could be suitable to be included in drug prescribing formularies, although zolpidem, zopiclone, and temazepam had higher scores and thus can be seen as relatively favorable.

Lormetazepam is considered a hypnotic benzodiazepine and is officially indicated for moderate to severe insomnia. Lormetazepam is a short-acting benzodiazepine and is sometimes used in patients who have difficulty in maintaining sleep or falling asleep. Hypnotics should only be used on a short-term basis or, in those with chronic insomnia, on an occasional basis.

...
Wikipedia